Search
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalIt can be administered orally or subcutaneously. … mycobacteria, improved cavity healing, improvements in immune parameters and reduced symptoms (fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without any adverse local or
Derazantinib
go.drugbank.com/drugs/DB14889InvestigationalDerazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
VS-4718
go.drugbank.com/drugs/DB15273InvestigationalVS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).
Telatinib
go.drugbank.com/drugs/DB15393InvestigationalTelatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).
Camidanlumab tesirine
go.drugbank.com/drugs/DB16411InvestigationalCamidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).
Danburstotug
go.drugbank.com/drugs/DB19064InvestigationalDanburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).
Quisinostat
go.drugbank.com/drugs/DB12985InvestigationalQuisinostat has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia.
Vactosertib
go.drugbank.com/drugs/DB15310InvestigationalVactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).
Cytidine-5'-Monophosphate-5-N-Acetylneuraminic Acid
go.drugbank.com/drugs/DB02485ExperimentalA nucleoside monophosphate sugar which donates N-acetylneuraminic acid to the terminal sugar of a ganglioside or glycoprotein. [PubChem]
AZD-8330
go.drugbank.com/drugs/DB06061InvestigationalAZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of h...